Chugai Pharmaceutical’s ALK inhibitor Alecensa (alectinib) reduced the risk of disease progression or death by 63% versus Pfizer’s Xalkori (crizotinib) in a Japan PIII study, which assessed the agents in a first-line setting for ALK-positive non-small cell lung cancer (NSCLC),…
To read the full story
Related Article
- Alecensa Japan PIII Trial Halted Early for Benefit
February 12, 2016
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





